idea-003 · business case
Who pays, from which budget, how much, and 2-4 commercial routes to first revenue — every figure below traces to a copied claim or a declared assumption, and the routes are laid out unranked. Choosing a commercial strategy is a Tier 3 act, so this page presents options and stops.
Intended use: For Research Use Only, not for use in diagnostic procedures — intended for use by molecular laboratories to characterize the limit of detection, specificity, and inter-run precision of tumor-informed circulating tumor DNA minimal residual disease assays during assay development and ongoing performance monitoring.
This is a laboratory reagent, not a reimbursed therapy — there is no payer leg in this chain at all. The whole chain is one cheque, written by a laboratory or a company out of its own operating budget.
adoption-class and
permanently unverifiable (see below), not a fact this repo can check.
unconfirmed.
unconfirmed and adoption-class.
The chain's weakest link is its first one. The buyer's ability to purchase this consumable without a capital-procurement process is itself an unconfirmed, permanently unverifiable adoption claim [claim 26: unconfirmed] — the same disposition as whether the buyer prefers this product over what it already has [claim 21: unconfirmed].
Decomposed, not asserted. Nothing below is this product's own claimed revenue — it is arithmetic over a downstream test's Medicare pricing, folded through an unverifiable spend share, because that downstream test's economics are the only checkable primitive this candidate's TAM claims contain. Read the caveats beside every row.
| Line | Figure | Backing |
|---|---|---|
| Downstream test (0340U, Natera Signatera) Medicare payment rate, 7/1/21-3/31/22 period | $3,500.00 | [claim 9: unconfirmed] — fixable gap, missing local CMS cache |
| Downstream test annual Medicare claim volume | >100,000 tests (a Medicare FFS floor, never a market size — excludes Medicare Advantage, commercial, Medicaid, VA, cash-pay) | [claim 10: unconfirmed] — fixable gap, missing local CMS cache |
| Downstream Medicare test revenue (arithmetic, not itself claimed by any line in the file) | ~$350,000,000 | arithmetic over [claim 9: unconfirmed] × [claim 10: unconfirmed] |
| Reference material / external QC spend as a share of laboratory test revenue | 0.5%-1.5% | [claim 11: unconfirmed] — market-class, permanently unverifiable |
| Initial obtainable spend pool, whole discipline, arithmetic only | ~$1,750,000-$5,250,000/yr | arithmetic over [claim 9: unconfirmed] × [claim 10: unconfirmed] × [claim 11: unconfirmed]; no claim in the file asserts this composite, and it inherits every caveat those three claims carry |
| Addressable US laboratory count (the segment actually reachable, not the whole pool above) | 30-60 laboratories running or developing tumor-informed MRD assays | [claim 12: unconfirmed] — market-class, permanently unverifiable |
| Recurrence of control-material consumption (mechanism, not a magnitude) | at least once daily per molecular amplification procedure, mandatory under CLIA | [claim 7: verified] — verifies that consumption is mandatory and daily; does not verify that it is purchased from a third party rather than built in-house, and does not verify commutability is required |
| Purchasing cadence — recurring vs. one-time | asserted as tied to assay-run cadence and periodic revalidation, not established as fact | [claim 27: unconfirmed] |
| Share of the addressable pool this product captures by year 3, vs. in-house builds and the three incumbents | not established anywhere in the file | [assumption A1] |
| Price per panel to a laboratory customer | not established | [assumption A2] |
| Gross margin on the panel at achievable price and volume | not established | [assumption A3] |
| Panel price × addressable lab count supporting a standalone business rather than a product line inside a larger reagent company | asserted, not measured | [claim 29: unconfirmed] |
Read the largest number first. It is the initial obtainable spend pool, and it is arithmetic over one downstream test's Medicare-only pricing (itself blocked on two missing local CMS caches, [claim 9: unconfirmed], [claim 10: unconfirmed]) folded through a permanently unverifiable market-share percentage [claim 11: unconfirmed]. Even in the best case where the two fixable-gap claims resolve, a Medicare FFS claim volume is a floor on US volume, never a market size — it excludes Medicare Advantage, commercial, Medicaid, VA, and cash-pay entirely. And none of this number is this product's own revenue in the first place: it is the whole discipline's spend pool, before [assumption A1]'s capture share, [assumption A2]'s price, or [assumption A3]'s margin are applied to it.
The two connectors that would ordinarily carry a business case both refuse, and the verdicts go on the page rather than being routed around:
python3 -m connectors market "Reference material and external QC spend for tumor-informed ctDNA MRD assay validation represents an addressable market of roughly 0.5-1.5% of laboratory test revenue across the 30-60 US laboratories running or developing these assays" → unverifiable — "Market-size claim (...) has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
python3 -m connectors adoption "MRD laboratories will pay a recurring per-panel price for a third-party commutable reference material rather than continuing to build in-house contrived controls" → unverifiable — "Adoption/preference claim (...) asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study). Stays unconfirmed permanently unless a human attaches real research and edits the claim by hand. Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim."
The connector's own suggested rescope for coverage/procedures does not apply here in the usual sense: there is no reimbursed comparator for this product itself — Factor 2 was left blank rather than scored for exactly that reason — and the procedures/payment primitives above are already the closest checkable proxy available, borrowed from the downstream test this product's customers themselves bill for.
Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act — the same class of decision as choosing what to shortlist — so this section presents options and stops.
The route the candidate file already describes: sell the panel as a research-use consumable, outside premarket review, direct to the 30-60 laboratory segment.
The candidate's own planned second SKU, once revenue from Route A exists to carry quality-system cost: daily QC material for a clinical MRD test rather than an assay-development reagent.
The regulation FDA's own classification database points at for DNA/genetics quality control material, and the fallback route named in the candidate's frontmatter.
Sell the differentiator, not the panel: an OEM technology-transfer or licensing deal with one of the three named incumbent reference-material vendors, rather than fielding an independent direct-sales channel.
PATENTSVIEW_API_KEY is unset in this checkout [claim 18: unconfirmed].
Every assumption cited above, with what would settle it and who could run it. These are appended to the candidate as unverified claims 47-51 via append_commercial_claims.py.
| # | Assumption | Falsifier | Owner |
|---|---|---|---|
| A1 | By year 3, a third-party commercial reference panel captures at least a low double-digit percentage share of addressable US MRD-laboratory reference-material spend, rather than losing that spend to in-house contrived controls or the three incumbent commercial vendors | Named customer-discovery interviews with 10-15 MRD laboratory directors and assay-development scientists on current reference-material source and switching willingness; connectors adoption returns unverifiable by design, so this needs primary research, not a connector re-run | Commercial / business development |
| A2 | A molecular laboratory or assay manufacturer will pay a per-panel price materially above the incumbent commercial reference-material vendors' list price (LGC Seraseq, Horizon/Revvity HDx, Twist Bioscience) for a panel characterized into the sub-0.01% VAF range | A pricing survey collecting current list or quoted prices for the three named incumbent products from distributor price lists or direct vendor quotes, compared against a target price for this panel | Commercial / business development |
| A3 | The gross margin earned on the panel, once donor-plasma sourcing, orthogonal dPCR characterization, and ISO 17034-oriented documentation costs are included, is high enough to support a standalone reference-material business at the addressable laboratory count and purchase cadence | A bottom-up bill-of-materials and cost-of-goods roll-up — donor plasma cost per liter from a vendor contract, dPCR platform run cost and throughput, ISO 17034 documentation labor hours — quoted at stated production volumes | Engineering + operations |
| A4 | First commercial shipment of a characterized panel to a paying laboratory customer is achievable within the same low-single-digit-million capital budget and a calendar of roughly 9-15 months from a standing start | A bottom-up build plan naming lead times for a dPCR platform purchase, a consented donor-plasma sourcing contract, and ISO 17034 accreditation (claim 33), sequenced into a critical-path calendar | Commercial / business development + regulatory operations |
| A5 | An existing reference-material vendor (LGC Clinical Diagnostics, Revvity/Horizon Discovery, or Twist Bioscience) would license or acquire sub-0.01%-VAF characterization and orthogonal dPCR quantification methodology rather than build it in-house, at a cost and calendar lower than fielding an independent direct-sales channel to the 30-60 laboratory segment | Direct outreach to business-development contacts at the three named vendors, or a signed term sheet, establishing licensing interest and terms, benchmarked against the cost of building the Route A direct-sales channel [claim 28: unconfirmed] | Business development / corporate development |
Every figure with no claim behind it, gathered in one place — the work items.